A six month randomized controlled trial of long acting injectable risperidone 50 and 100 mg in treatment resistant schizophrenia

Schizophrenia Research

Volumn 154, Issue 1-3, 2014, Pages 14-22

  Meltzer, H Y ^a   Lindenmayer, J P ^b   Kwentus, J ^c   Share, D B ^a   Johnson, R ^a   Jayathilake, K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Precise Research Center   (United States)

Author keywords

Extrapyramidal; Long acting injectable; Prolactin; Risperidone; Schizophrenia; Treatment resistant

Indexed keywords

PALIPERIDONE; RISPERIDONE; DELAYED RELEASE FORMULATION; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SLEEP DISORDER; SUICIDAL BEHAVIOR; TREATMENT DURATION; ADOLESCENT; BLOOD; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOSE RESPONSE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897028957     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.02.015     Document Type: Article

References (58)

1. Azorin J.M., Spiegel R., Remington G., Vanelle J.M., Pere J.J., Giguere M., Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am. J. Psychiatry 2001, 158(8):1305-1313.
2. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
3. Beerpoot L.J., Lipska B.K., Weinberger D.R. Neurobiology of treatment-resistant schizophrenia: new insights and new models. Eur. Neuropsychopharmacol. 1996, 6(Suppl. 2):S27-S34.
4. Bitter I., Dossenbach M.R., Brook S., Feldman P.D., Metcalfe S., Gagiano C.A., Furedi J., Bartko G., Janka Z., Banki C.M., Kovacs G., Breier A., Olanzapine, H.S.G. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(1):173-180.
5. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P. Risperidone versus clozapine in treatment- resistant chronic schizophrenia: a randomized double- blind study. The Risperidone Study Group. Am. J. Psychiatry 1998, 155(4):499-504.
6. Canas F., Moller H.J. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. Expert Opin. Drug Saf. 2010, 9(5):683-697.
7. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 1993, 13(1):25-40.
8. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1977, Lawrence Erlbaum Associates, Hillsdale, NJ. 1st ed.
9. Conley R.R., Kelly D.L., Nelson M.W., Richardson C.M., Feldman S., Benham R., Steiner P., Yu Y., Khan I., McMullen R., Gale E., Mackowick M., Love R.C. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin. Neuropharmacol. 2005, 28(4):163-168.
10. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 2004, 161(3):414-425.
11. Curtis V.A., Katsafouros K., Moller H.J., Medori R., Sacchetti E. Long-acting risperidone improves negative symptoms in stable psychotic patients. J. Psychopharmacol. 2008, 22(3):254-261.
12. Darby J.K., Pasta D.J., Elfand L., Dabiri L., Clark L., Herbert J. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J. Clin. Psychopharmacol. 1997, 17(6):478-484.
13. Eerdekens M., Van Hove I., Remmerie B., Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 2004, 70(1):91-100.
14. Elkis H. History and Current Definitions of Treatment-resistant Schizophrenia Adv Biol Psychiatry 2010, Karger, Basel.
15. Ermilov M., Gelfin E., Levin R., Lichtenberg P., Hashimoto K., Javitt D.C., Heresco-Levy U. A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Schizophr. Res. 2013, 150(2-3):604-605.
16. Fleischhacker W.W., Eerdekens M., Karcher K., Remington G., Llorca P.M., Chrzanowski W., Martin S., Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry 2003, 64(10):1250-1257.
17. Girardi P., Serafini G., Pompili M., Innamorati M., Tatarelli R., Baldessarini R.J. Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry 2010, 43(2):66-72.
18. Glick I.D., Correll C.U., Altamura A.C., Marder S.R., Csernansky J.G., Weiden P.J., Leucht S., Davis J.M. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J. Clin. Psychiatry 2011, 72(12):1616-1627.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology: revised (DHEW publication number ADM 76-338) 1976, 534-537. (Rockville, MD). US Department of Health, E.a.W., Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs (Eds.).
20. Janicak P.G., Javaid J.I., Sharma R.P., Leach A., Dowd S., Davis J.M. A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Acta Psychiatr. Scand. 1997, 95(4):343-350.
21. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
22. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003, 160(6):1125-1132.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
24. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Sniadecki J.L., Kane J.M. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr. Res. 2008, 102(1-3):230-240.
25. Kishimoto T., Robenzadeh A., Leucht C., Leucht S., Watanabe K., Mimura M., Borenstein M., Kane J.M., Correll C.U. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr. Bull. 2013, 40(1):192-213. (Jan).
26. Kumra S., Kranzler H., Gerbino-Rosen G., Kester H.M., De Thomas C., Kafantaris V., Correll C.U., Kane J.M. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol. Psychiatry 2008, 63(5):524-529.
27. Kumra S., Kranzler H., Gerbino-Rosen G., Kester H.M., DeThomas C., Cullen K., Regan J., Kane J.M. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. J. Child Adolesc. Psychopharmacol. 2008, 18(4):307-316.
28. Lee M.L., Dickson R.A., Campbell M., Oliphant J., Gretton H., Dalby J.T. Clozapine and substance abuse in patients with schizophrenia. Can. J. Psychiatry 1998, 43(8):855-856.
29. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14(4):429-447.
30. Lieberman J.A., Safferman A.Z., Pollack S., Szymanski S., Johns C., Howard A., Kronig M., Bookstein P., Kane J.M. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry 1994, 151(12):1744-1752.
31. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987, 334:1-100.
32. Liu G., Gould A.L. Comparison of alternative strategies for analysis of longitudinal trials with dropouts. J. Biopharm. Stat. 2002, 12(2):207-226.
33. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 1994, 151(6):825-835.
34. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Davis J.M., Kane J.M., Lieberman J., Schooler N.R. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr. Bull. 2002, 28(1):5-16.
35. Mauri M.C., Laini V., Boscati L., Rudelli R., Salvi V., Orlandi R., Papa P. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur. Psychiatry 2001, 16(1):57-63.
36. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K., Investigators C. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163(4):600-610.
37. Medori R., Mannaert E., Grunder G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur. Neuropsychopharmacol. 2006, 16(4):233-240.
38. Melnik T., Soares B.G., Puga M.E., Atallah A.N. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. Sao Paulo Med. J. 2010, 128(3):141-166.
39. Meltzer H.Y. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch. Gen. Psychiatry 1989, 46(7):672.
40. Meltzer H.Y. Treatment-resistant schizophrenia-the role of clozapine. Curr. Med. Res. Opin. 1997, 14(1):1-20.
41. Meltzer H.Y. Clozapine: balancing safety with superior antipsychotic efficacy. Clin. Schizophr. Relat. Psychoses 2012, 6(3):134-144.
42. Meltzer H.Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 2013, 64:393-406.
43. Meltzer H.Y., Bobo W.V., Roy A., Jayathilake K., Chen Y., Ertugrul A., Anil Yagcioglu A.E., Small J.G. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 2008, 69(2):274-285.
44. 2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr. Res. 2012, 141(2-3):144-152.
45. Meltzer H.Y., Massey B.W., Horiguchi M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr. Pharm. Biotechnol. 2012, 13(8):1572-1586.
46. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 2000, 101(4):323-329.
47. Nasrallah H.A., Duchesne I., Mehnert A., Janagap C., Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J. Clin. Psychiatry 2004, 65(4):531-536.
48. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry 1995, 166(6):712-726. (discussion 727-733).
49. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. 1997, 337(12):809-815.
50. Rosenheck R., Evans D., Herz L., Cramer J., Xu W., Thomas J., Henderson W., Charney D. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr. Bull. 1999, 25(4):709-719.
51. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
52. Taylor D.M., Young C., Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J. Clin. Psychiatry 2003, 64(1):30-34.
53. Tollefson G.D., Birkett M.A., Kiesler G.M., Wood A.J., Lilly Resistant Schizophrenia Study, G Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 2001, 49(1):52-63.
54. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2002, 159(2):255-262.
55. Volonteri L.S., Cerveri G., De Gaspari I.F., Baldi M.L., Rolandi M.L., Papa P., Mauri M.C., Mencacci C. Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients. Psychopharmacology (Berl) 2010, 210(4):489-497.
56. Weissman E.M. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr. Bull. 2002, 28(1):31-42.
57. Wirshing D.A., Marshall B.D., Green M.F., Mintz J., Marder S.R., Wirshing W.C. Risperidone in treatment-refractory schizophrenia. Am. J. Psychiatry 1999, 156(9):1374-1379.
58. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8(3):457-472.